Very poor long-term outcomes for people with TB and HIV in Eastern Europe
Once-daily dolutegravir sufficient when taking TB treatment
What will it take to end advanced HIV disease-related deaths?
Shorter, less toxic treatment for highly drug-resistant TB cures nine out of ten
Four-month TB treatment matches six-month standard of care
COVID-19 casts a shadow over progress on TB
Disruption to HIV treatment in Africa during COVID-19 pandemic could double HIV deaths, modelling studies warn
New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin
One-third of people living with HIV in rural Tanzania report clinically relevant drug-drug interactions
